Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark Levin
AddedMar 31, 2024
UpdatedMay 31, 2026
Mark Levin

Mark Levin

Co-Founder, Third Rock Ventures

CrunchbaseLinkedIn

Mark Levin's Career

Third Rock Ventures
Third Rock Ventures

Boston, MA, US

Co-Founder
Mayfield Fund
Mayfield Fund

Menlo Park, CA, US

CEO· C-Suite · Management
Fulcrum Therapeutics
Fulcrum Therapeutics

Cambridge, MA, US

Board Member· Board
NinePoint Medical
NinePoint Medical

Bedford, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark Levin's Career

Third Rock Ventures
Third Rock Ventures
Investment Firm1482007Boston, MA, US
Co-Founder

Leadership at Third Rock Ventures

Kevin StarrKevin StarrCo-Founder
Robert TepperRobert TepperCo-Founder
Mayfield Fund
Mayfield Fund
Investment Firm151969Menlo Park, CA, US
CEO· C-Suite · Management

Recent news

Former Infosys chief has a new startup that wants to challenge the IT services worldTechCrunch · 2026
Two Stanford students launch $2M startup accelerator for students nationwideTechCrunch · 2026
Numeral Raises $35 Million in Series B FundingBusiness Wire · 2025

Leadership at Mayfield Fund

Rishi GargRishi GargBoard Member
Doug SchmidtDoug SchmidtBoard Member
Ben GolubBen GolubBoard Member
Thomas J. Davis, Jr.Thomas J. Davis, Jr.Founder
Fulcrum Therapeutics
Fulcrum Therapeutics
Public$603.3M892016Cambridge, MA, US
Board Member· Board

Leadership at Fulcrum Therapeutics

Robert GouldRobert GouldBoard Member
James GeraghtyJames GeraghtyBoard Member
Jeannie T. LeeJeannie T. LeeFounder
Kate HavilandKate HavilandBoard Member
Alex SapirAlex SapirBoard Member
Katina DortonKatina DortonBoard Member

Similar to Fulcrum Therapeutics

Fulcrum PharmaceuticalsFulcrum PharmaceuticalsHenderson, NV, USDrug Developmentest. 2002Fulcrum PharmaceuticalsHenderson, NV, US · est. 2002

Fulcrum Pharmaceuticals: Innovating drug development through computational chemistry and biology since 2002.

Series A · $8M6
Astria TherapeuticsAstria TherapeuticsBoston, MA, USBiopharmaceuticalsest. 2008Astria TherapeuticsBoston, MA, US · est. 2008

Astria Therapeutics, Inc.: A clinical-stage biopharmaceutical company developing treatments for rare diseases and lipid disorders.

Public · $656.4M24
CAMP4 TherapeuticsCAMP4 TherapeuticsCambridge, MA, USTherapeuticsest. 2016CAMP4 TherapeuticsCambridge, MA, US · est. 2016

CAMP4 Therapeutics: A Massachusetts-based biotech firm specializing in disease treatment therapies.

Series B · $190M84
Triplet TherapeuticsTriplet TherapeuticsCambridge, MA, USBiotechnologyest. 2019Triplet TherapeuticsCambridge, MA, US · est. 2019

Triplet Therapeutics: Pioneering biotech firm developing transformative treatments for genetic diseases.

Series A · $59M36
NinePoint Medical
NinePoint Medical
$112.7M02008Bedford, MA, US
Board Member· Board

Leadership at NinePoint Medical

Chuck CarignanChuck CarignanFounder
Eric SwansonEric SwansonBoard Member
Eman NamatiEman NamatiCEO
Russell HirschRussell HirschBoard Member
Thomas J Miller JrThomas J Miller JrBoard Member
Chris Von JakoChris Von JakoBoard Member

People Similar to Mark Levin

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · Dunamu